Who
Andrew Gengos
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Immuneering; Director, Turn Therapeutics; Chief Financial Officer, Terns Pharmaceuticals; CFO and Chief Business Officer, LeonaBio; Chief Business Officer, Cyteir Therapeutics; Chief Operating Officer, Synlogic; President and CEO, ImmunoCellular Therapeutics.
In numbers
- Trades disclosed
- 58
- Buys
- 10
- Sells
- 3
- Bought
- $397K
- Sold
- $7,756
- Companies
- 7
- Companies where not an officer
- 1
- First trade
- 3 Dec 2012
- Last trade
- 16 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 17 Jul 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | TTRX Turn Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | TTRX Turn Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns PharmaceuticalsBiotechnology | SEC FORM 4 Code U | $2.1M40,503 at $53.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $3.6M68,750 at $53.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —750,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —750,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —137,500 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —137,500 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticals | SEC FORM 4 Code U | $2.1M40,503 at $53.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticals | SEC FORM 4 Code D | $3.6M68,750 at $53.00 | filing |
| 14 Jan 2026filed 16 Jan 2026 | Terns PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —68,750 at $0.00 | filing |
| 14 Jan 2026filed 16 Jan 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,500 at $0.00 | filing |
| 14 Jan 2026filed 16 Jan 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —137,500 at $0.00 | filing |
| 14 Jan 2026filed 16 Jan 2026 | Terns Pharmaceuticals | SEC FORM 4 Code A | —68,750 at $0.00 | filing |
| 8 Oct 2025filed 10 Oct 2025 | TTRX Turn TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 27 Jun 2025filed 30 Jun 2025 | Terns Pharmaceuticals | SEC FORM 4 Bought | $20K5,000 at $3.93 | filing |
| 27 Jun 2025filed 30 Jun 2025 | Terns Pharmaceuticals | SEC FORM 4 Bought | $20K5,000 at $3.93 | filing |
| 16 Jun 2025filed 16 Jun 2025 | Terns Pharmaceuticals | SEC FORM 4 Bought | $20K5,000 at $3.95 | filing |
News
Athira Pharma (NASDAQ:LONA) Upgraded at Wall Street ZenLONA · dailypolitical.com · 20 Oct 2026
0 headlines in the last 90 days name Andrew Gengos; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.